1. Home
  2. AIHS vs ENTO Comparison

AIHS vs ENTO Comparison

Compare AIHS & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIHS
  • ENTO
  • Stock Information
  • Founded
  • AIHS 2014
  • ENTO 2014
  • Country
  • AIHS China
  • ENTO United States
  • Employees
  • AIHS N/A
  • ENTO N/A
  • Industry
  • AIHS Finance: Consumer Services
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • AIHS Finance
  • ENTO Health Care
  • Exchange
  • AIHS Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • AIHS 2.2M
  • ENTO 2.3M
  • IPO Year
  • AIHS 2018
  • ENTO 2016
  • Fundamental
  • Price
  • AIHS $1.75
  • ENTO $4.46
  • Analyst Decision
  • AIHS
  • ENTO
  • Analyst Count
  • AIHS 0
  • ENTO 0
  • Target Price
  • AIHS N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • AIHS 127.4K
  • ENTO 193.9K
  • Earning Date
  • AIHS 11-13-2025
  • ENTO 11-14-2025
  • Dividend Yield
  • AIHS N/A
  • ENTO N/A
  • EPS Growth
  • AIHS N/A
  • ENTO N/A
  • EPS
  • AIHS N/A
  • ENTO N/A
  • Revenue
  • AIHS $3,370,162.00
  • ENTO N/A
  • Revenue This Year
  • AIHS N/A
  • ENTO N/A
  • Revenue Next Year
  • AIHS N/A
  • ENTO N/A
  • P/E Ratio
  • AIHS N/A
  • ENTO N/A
  • Revenue Growth
  • AIHS 8.56
  • ENTO N/A
  • 52 Week Low
  • AIHS $1.63
  • ENTO $0.97
  • 52 Week High
  • AIHS $17.00
  • ENTO $5.84
  • Technical
  • Relative Strength Index (RSI)
  • AIHS 40.05
  • ENTO 54.37
  • Support Level
  • AIHS $1.63
  • ENTO $3.89
  • Resistance Level
  • AIHS $2.01
  • ENTO $5.09
  • Average True Range (ATR)
  • AIHS 0.11
  • ENTO 0.65
  • MACD
  • AIHS -0.03
  • ENTO -0.18
  • Stochastic Oscillator
  • AIHS 20.34
  • ENTO 33.01

About AIHS Senmiao Technology Limited

Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: